Korsch AG recently announced that has acquired Medelpharm and its compaction simulator technology. The financial terms of the deal were not disclosed. Korsch said Medelpharm’s compaction simulator technology adds early-stage material characterization and scale-up capability to its R&D product portfolio. The companies have 135-plus years of experience with small-scale, fully instrumented tablet compression equipment. The Korsch…
Cardinal Health pharmaceutical segment grows sales 15% in Q2
Cardinal Health (NYSE: CAH) today posted second-quarter results that beat the overall consensus on Wall Street. The Dublin, Ohio-based company reported losses of $130 million, or 50¢ per share, on sales of $51.5 billion for the three months ended December 31, 2022. Cardinal Health’s results swung to a loss versus the same quarter a year…
Why remote ketamine prescribing could change in May
Ketamine continues to gain in popularity as an off-label treatment for mood disorders. During the pandemic, remote telepsychiatry companies have gained in popularity, facilitating remote prescribing of sublingual ketamine. That practice may change on May 11, when the White House plans to end the COVID-19 public health emergency (PHE). The PHE enabled companies such as…
Pharma layoffs in 2023: Companies making cuts
A recession in 2023 is highly probable. Some two-thirds of economists surveyed at the World Economic Forum in Davos said they anticipated an economic downturn this year. Given the difficult economic situation, a growing number of pharmaceutical firms are reducing staff. Several companies announced cuts at the end of 2022, including Catalent and Novartis. The…
Biopharma company Chiesi appoints former Medtronic exec as CEO
Chiesi announced today that it appointed former Baxter and Medtronic executive Giuseppe Accogli as its new group CEO. Parma, Italy–based Chiesi said Accogli’s appointment becomes effective April 3, 2023. The R&D-focused pharmaceutical company develops and commercializes products for the hospital, rare disease and adjacent specialty care settings. Accogli brings 25 years of international experience to…
Vaccitech names Nadège Pelletier as chief scientific officer
The clinical-stage biopharma Vaccitech (Nasdaq:VACC) has appointed Nadège Pelletier as its new chief scientific officer. She will lead scientific teams in drug discovery and platform development at the company and will oversee its technical strategy. Vaccitech is a UK-based biotech that develops vaccines and immunotherapies. “It’s an exciting time to be joining Vaccitech,” Pelletier said in…
Cardinal Health, Palantir partner on AI for pharmaceutical products
Cardinal Health (NYSE:CAH) announced that it entered into a strategic collaboration with Palantir Technologies (NYSE:PLTR). The partnership pairs the companies to design a solution to give health systems and hospitals dynamic purchase decision insights. These insights help them quickly improve their bottom line. Dublin, Ohio-based Cardinal Health plans to integrate this solution into Foundry, Palantir’s…
For the sake of sustainability, put people at your core
It’s no secret the pharmaceutical industry has been slow to adopt sustainability practices. Unlike other industries, end users haven’t demanded products be made “greener.” In manufacturing, sustainability is still considered a cost rather than an investment. New technologies and innovative solutions may promise to deliver results, but many take years to show any return. In…
Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility
Eli Lilly (NYSE:LLY) announced today that it plans to invest an additional $450 million at a North Carolina manufacturing facility. Lilly expects the investment to create at least 100 new jobs at the Research Triangle Park, North Carolina, plant. Its expansion includes additional parenteral filling, device assembly and packaging capacity. Indianapolis-based Lilly said this expansion supports…
Johnson & Johnson reports mixed Q4 results amid shaky economy
Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…